Phase 2 Mesothelioma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with certain types of cancer confirmed by a lab test, including head and neck cancers, esophageal cancer, lung cancers, mesothelioma, pancreatic cancers, or any solid tumour or lymphoma that has a specific gene change called NTRK1 fusion — and whose cancer has come back, stopped responding to standard treatment, or who cannot tolerate standard treatment, with no other approved or curative treatment options remaining.
• People whose general health and ability to carry out daily activities meets a specific level (called ECOG Performance Status 0 or 1, meaning fully active or able to carry out light work — confirm with trial site).
• People who are able to swallow and keep down tablets or capsules taken by mouth.
• People who either have stored tumour tissue samples available, or who agree to have a tumour tissue sample taken before starting the trial.
• People whose blood counts, liver function, kidney function, and blood clotting results fall within the required ranges as determined by the trial team (confirm with trial site for specific values).

Who may not be able to join:

• People who have received certain chemotherapy treatments within the past 14 days (or six weeks for specific types called nitrosourea or mitomycin C).
• People who have had radiation therapy, immunotherapy, biological therapy, surgery, or tumour embolisation within the past two weeks.
• People who have taken another experimental cancer drug within 14 days or five half-lives of that drug (whichever is longer) before starting this trial.
• People who still have unresolved side effects from previous cancer treatment that are above a mild level (with the exception of hair loss or anaemia), unless agreed upon by the trial medical team.
• People with known active infections, including HIV.
• People who are currently pregnant, breastfeeding, or planning to become pregnant during the study.
• People with a specific abnormality in heart electrical activity (QTcF interval of 480 milliseconds or more — confirm with trial site).
• People with moderate to severe heart failure (classified as Class II, IV, or IV by a standard medical scale).
• People who have had a heart attack, unstable chest pain, or a heart procedure (such as stenting or angioplasty) within the past 24 weeks.
• People with unstable or poorly controlled breathing, liver, kidney, or heart problems that could affect their safety or interfere with the study results.
• People with psychological, family, social, geographical, or other personal circumstances that could affect their ability to safely follow the trial procedures, including those with uncontrolled major depression, bipolar disorder, or severe anxiety disorder.
• People who have had or currently have another type of cancer within the past three years.
• People who have conditions that affect their ability to take oral (by mouth) medications reliably.
• People with long-term wounds or broken bones that have not healed.
• People with uncontrolled fluid build-up around the lungs, heart, or abdomen that still requires repeated draining.
• People who are taking, and cannot stop taking, the following medications during the study: products containing acetaminophen (paracetamol, such as Tylenol); antacids (such as TUMS, calcium carbonate, or magnesium hydroxide); proton pump inhibitors (such as omeprazole); H2 blockers (such as famotidine); or buffered vitamins.
• People with a specific type of throat cancer (nasopharyngeal carcinoma) that tests negative for the Epstein-Barr virus.
• (Phase 2 only) People whose tumour tests negative for a protein called TrkA on a specific lab test.
• (Phase 2 only) People experiencing a severe and rapid worsening of organ function related to their cancer (called visceral crisis).
• (Combination therapy arm only) People who previously had serious (grade 3 or 4) immune-related side effects from a type of immunotherapy called a PD-1 or PD-L1 inhibitor, which were symptomatic and required prolonged immune-suppressing treatment for more than six weeks.
• (Combination therapy arm only) People who previously experienced any level of lung inflammation (pneumonitis) or heart muscle inflammation (myocarditis) related to a PD-1 or PD-L1 inhibitor.
• (Combination therapy arm only) People who previously received a PD-1 or PD-L1 inhibitor and had their cancer respond well (complete or partial response) but then had the cancer return after stopping that treatment.
• (Combination therapy arm only) People who received a PD-1 or PD-L1 inhibitor less than 21 days before the planned start date of the trial medications.

Important: Always verify eligibility with the trial site directly before applying.